Johnson & Johnson’s monoclonal antibody Imaavy succeeded in a mid-stage lupus trial, bringing the company one step closer to its goal of expanding the drug in other autoimmune diseases.
Imaavy met its primary endpoint of …
Read More from Endpoints News